Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer.
Publication/Presentation Date
9-1-2022
Abstract
Colorectal cancer remains a major cause of mortality in the USA, despite advances in prevention and screening. Existing therapies focus primarily on generic treatment such as surgical intervention and chemotherapy, depending on disease severity. As personalized medicine and targeted molecular oncology continue to develop as promising treatment avenues, there has emerged a need for effective targets and biomarkers of colorectal cancer. The transmembrane receptor guanylyl cyclase C (GUCY2C) regulates intestinal homeostasis and has emerged as a tumor suppressor. Further, it is universally expressed in advanced metastatic colorectal tumors, as well as other cancer types that arise through intestinal metaplasia. In this context, GUCY2C satisfies many characteristics of a compelling target and biomarker for gastrointestinal malignancies.
Volume
19
Issue
5
First Page
457
Last Page
472
ISSN
1744-828X
Published In/Presented At
Caspi, A., Entezari, A. A., Crutcher, M., Snook, A. E., & Waldman, S. A. (2022). Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer. Personalized medicine, 19(5), 457–472. https://doi.org/10.2217/pme-2022-0026
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
35920071
Department(s)
Administration and Leadership
Document Type
Article